CervoMed Inc. announced clinical, plasma biomarker, and imaging data for its lead drug candidate, neflamapimod, in treating dementia with Lewy bodies, which was presented at the Alzheimer's Association International Conference 2026. CervoMed Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.
